Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography

Clinical Nuclear Medicine

Volumn 25, Issue 10, 2000, Pages 789-795

  Hwang, Kyunghoon ^a   Park, Chan H ^a   Kim, Hugh C ^a   Kim, Hyunsoo ^a   Yoon, Seoknam ^a   Pai, Moonsun ^a   Kim, Suzy ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Coincidence Positron Emission Tomography; Dual head Gamma Camera; F 18 Fluorodeoxyglucose; Lymphoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; AGED; ARTICLE; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE RECONSTRUCTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; SCINTILLATION CAMERA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GAMMA CAMERAS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033803156     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200010000-00008     Document Type: Article

References (47)

1. Cancer statistics
2. Lymphography for staging of lymphomas: Is it still a useful procedure?
3. How useful is mediastinoscopy today?
4. Hodgkin's disease: Contribution of chest CT in the initial staging evaluation
5. Computed tomography of the abdomen and pelvis in non-Hodgkin lymphoma
6. Magnetic resonance imaging in the initial staging of Hodgkin's disease and non-Hodgkin lymphoma
7. Imaging of childhood non-Hodgkin lymphoma assessment by histologic subtype
8. A prospective study of magnetic resonance imaging in lymphoma staging
9. Early detection of lymphoma recurrence with gallium-67 scintigraphy
10. Ga-67 SPECT before and after treatment of lymphoma
11. High-dose gallium imaging in lymphoma
12. Positron emission tomography in oncology
13. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
14. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose
15. Non-small cell lung cancer: Nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling
16. Wholebody positron emission tomography in clinical oncology: Comparison between attenuation-corrected and uncorrected images
17. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma
18. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study
19. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation and uptake with prognosis
20. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity
21. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxy-glucose scintigraphy
22. 18F]-FDG: Correlation with CT
23. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
24. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging
25. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
26. Extranodal malignant lymphoma: Detection with FDG PET versus CT
27. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
28. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
29. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
30. Positron emission tomography with F-18-FDG to detect residual disease after therapy for malignant lymphoma
31. 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
32. Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma camera
33. Technology for FDG SPECT with a relatively inexpensive gamma camera
34. FDG SPECT: Correlation with FDG PET
35. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): Initial evaluation in oncology and comparison with FDG PET
36. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose
37. Performance characteristics of a dual head coincidence camera for the detection of small lesions
38. Simultaneous SPECT and coincidence imaging using a dual detector scintillation camera-works in progress
39. Measured coincidence imaging parameters of clinical dual-head scintillation camera
40. Coincidence imaging with a dual-head scintillation camera
41. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: Dual-head coincidence gamma camera versus positron emission tomographic scanner
42. Fluorine-1 8-FDG detection of laryngeal cancer postradiotherapy using dual-head coincidence imaging
43. FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders
44. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma: Summary and description of a working formulation for clinical use
45. Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: Effects of non-uniform attenuation correction on lesion detection
46. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow
47. Detection of lymphoma in bone marrow by whole body positron emission tomography